Psilocybin is a naturally occurring psychedelic compound found in more than 200 species of mushrooms, commonly called “magic mushrooms.” It belongs to the tryptamine family of alkaloids, chemicals structurally similar to serotonin, which is the brain’s primary mood-regulating chemical. When ingested, psilocybin is rapidly converted in the body into its active form, psilocin, which produces profound changes in perception, mood, and thought that typically last four to six hours.
How Psilocybin Works in the Brain
Psilocybin itself is essentially a prodrug. Your body strips a phosphate group from the molecule almost immediately after ingestion, converting it into psilocin. Psilocin is the compound that actually crosses into the brain and produces psychedelic effects.
Once there, psilocin binds to serotonin receptors, particularly the 5-HT2A receptor. A study published in Neuropsychopharmacology confirmed this directly in humans for the first time: psilocybin produced dose-related receptor occupancy of up to 72%, and higher occupancy closely tracked with stronger subjective effects. In other words, the more serotonin receptors that psilocin activates, the more intense the experience.
This receptor activation triggers a cascade of changes in how different brain regions communicate. Normally, your brain operates through fairly stable, segregated networks. One of the most important is the default mode network, which is active during self-reflection, mind-wandering, and maintaining your sense of personal identity. Psilocybin consistently reduces connectivity within this network while increasing communication between brain regions that don’t usually talk to each other. The brain shifts from a modular, compartmentalized state to a more globally interconnected one. This disruption of normal patterns is thought to underlie the feelings of ego dissolution, novel thinking, and emotional breakthroughs that people report during psychedelic experiences.
Where Psilocybin Comes From
Psilocybin occurs naturally in fungi, most famously in the genus Psilocybe. The best-known species, Psilocybe cubensis, is the most widely cultivated psilocybin mushroom in the world. Its psilocybin content varies enormously depending on the strain, ranging from trace amounts to nearly 2% of the mushroom’s dry weight. Other species like Psilocybe bohemica contain between 0.11% and 1.34% psilocybin by dry weight, illustrating how much potency can differ from one mushroom to the next.
This natural variability is a significant practical issue. Two dried mushrooms of the same species but different strains, grown in different conditions, can contain wildly different amounts of psilocybin. This unpredictability is one reason clinical research uses synthetic psilocybin in precisely measured doses rather than raw mushrooms.
Albert Hofmann, the Swiss chemist also famous for discovering LSD, first isolated psilocybin from mushroom samples in 1958 and successfully synthesized it in the laboratory a year later. Western science had only been introduced to psilocybin-containing mushrooms the year before, in 1957, when mycologist Robert Gordon Wasson published an account of participating in a traditional Mazatec mushroom ceremony in Mexico.
What the Experience Feels Like
Effects typically begin 20 to 40 minutes after ingestion, peak at 60 to 90 minutes, and remain active for four to six hours total. In clinical settings, dosing follows a rough scale: 25 mg of synthetic psilocybin (equivalent to about 2.5 grams of dried Psilocybe cubensis) is considered a standard dose, 35 mg (about 3.5 grams) is a high dose, and 50 to 60 mg (5 to 6 grams) is considered supra-therapeutic.
At standard to high doses, people commonly report visual distortions (surfaces appearing to breathe or shift, vivid colors, geometric patterns), a heightened emotional state, a sense that ordinary objects or thoughts carry deep personal meaning, and altered perception of time. Many people describe a dissolving of boundaries between themselves and their surroundings, sometimes called ego dissolution. The experience can be deeply positive and even mystical, or it can be frightening and disorienting, often depending on the person’s mindset and environment.
Physical effects are generally mild. Slight increases in blood pressure, heart rate, and body temperature are common. Nausea is one of the most frequently reported side effects, particularly when consuming raw mushrooms rather than a purified compound.
Toxicity and Physical Safety
Psilocybin has an unusually wide margin of physical safety compared to most psychoactive substances. No lethal dose has been firmly established in humans. In animal studies, the lethal dose for mice was found to be 275 to 420 mg per kilogram of body weight, depending on the route of administration. For context, a high dose in humans is about 35 mg total, which for an average adult comes out to roughly 0.5 mg per kilogram. The gap between an active dose and a physically dangerous one is enormous.
Only two case reports of death attributed to psilocybin toxicity exist in the medical literature, and the scientific community has questioned the validity of at least one of them. The real physical risks involve cardiovascular effects, which means people with heart conditions face higher danger. The primary safety concerns at typical doses are psychological rather than physical: intense anxiety, panic, confusion, and, rarely, lasting psychological distress.
Psilocybin as a Potential Treatment
Psilocybin has moved further through the medical research pipeline than most people realize. The FDA granted breakthrough therapy designation for psilocybin twice: once in 2018 for treatment-resistant depression and again in 2019 for major depressive disorder. Breakthrough therapy status is reserved for treatments that show substantial improvement over existing options, and it accelerates the review process.
The clinical results driving this interest are striking. In systematic reviews of psilocybin for major depressive disorder, the compound has shown significant reductions in depression scores, often after just one or two dosing sessions combined with psychotherapy. Long-term follow-up data is particularly noteworthy: one study found that reductions in depression were sustained 4.5 years after treatment in up to 80% of participants. These are early results from relatively small trials, and larger phase III studies are still underway, but the consistency of the signal across multiple research groups is what has generated serious attention from regulators.
The brain connectivity changes described earlier may help explain why. By temporarily disrupting rigid patterns in the default mode network and increasing communication across brain regions, psilocybin appears to open a window of heightened neuroplasticity. In depressed patients, decreased default mode network rigidity and increased integration with other brain networks have been observed up to three weeks after a single dose. The prevailing theory is that this window, combined with guided psychotherapy, allows patients to break out of entrenched negative thought patterns.
Legal Status
Psilocybin remains a Schedule I controlled substance under US federal law, classified as having high abuse potential and no accepted medical use. This designation predates the modern wave of clinical research and creates significant barriers for scientists studying the compound, though the FDA’s breakthrough therapy designations signal that this classification may eventually be revisited.
At the state and local level, the legal landscape is shifting. Oregon became the first state to create a regulated framework for supervised psilocybin use, and Colorado followed with a similar measure. Several cities, including Denver, Oakland, and Washington, D.C., have deprioritized enforcement of psilocybin possession laws. Outside the US, legal status varies widely. Countries like Jamaica and Brazil have no restrictions on psilocybin mushrooms, while most of Europe and Asia maintain strict prohibition.